BRKRHealthcare · Medical DevicesThe 13 Wall Street analysts covering Bruker Corp. hold a median 12-month price target of $60 — +1.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 2 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bruker Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (57): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BRKR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1.0% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Aug 2026 | Citigroup | Maintains | Neutral | $60 → $53 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $44 → $60 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 7 July 2026 | Leerink Partners | Maintains | Outperform | $60 → $70 |
| 7 July 2026 | Leerink Partners | Maintains | Outperform | — |
| 29 June 2026 | Guggenheim | Maintains | Buy | — |
| 24 June 2026 | Barclays | Maintains | Overweight | — |
| 8 June 2026 | JP Morgan | Maintains | Overweight | — |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 7 May 2026 | Barclays | Maintains | Overweight | — |
| 7 May 2026 | Citigroup | Maintains | Neutral | — |
| 7 May 2026 | TD Cowen | Maintains | Hold | — |
| 7 May 2026 | UBS | Maintains | Neutral | — |
| 15 Apr 2026 | Barclays | Maintains | Overweight | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 30 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 13 Feb 2026 | Barclays | Maintains | Overweight | — |
| 13 Feb 2026 | Citigroup | Maintains | Neutral | — |
| 13 Feb 2026 | Goldman Sachs | Maintains | Sell | — |
| 13 Feb 2026 | TD Cowen | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BRKR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Bruker Corp. returned +103.4% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 9% of US stocks
Cheaper than 47% of US stocks
Cheaper than 29% of US stocks
Cheaper than 16% of US stocks
Higher than 39% of US stocks
Higher than 42% of US stocks
Higher than 62% of US stocks
Higher than 64% of US stocks
Higher than 28% of US stocks
Higher than 41% of US stocks
Higher than 66% of US stocks
Higher than 6% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bruker Corp. has a market value of $8.5B and an enterprise value of $10.6B.
Revenue in the twelve months to 30 June 2026: $3.5B. The latest quarter grew 5.2% year on year.
Net income over the same four quarters: −$64.5M, a −1.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.70.
Free cash flow in the twelve months to 30 June 2026: $64.5M.
Bruker Corp. spent $54.7M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 74.9×; forward P/E: 23.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.36%, paying out 38% of earnings.
Bruker Corp. employs 11,085 people — $316K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bruker Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bruker (BRKR) reported earnings 30 days ago and its stock has risen 12.5% since that report. The item discusses what may be next for the company following the earnings release.
Why it matters — The double-digit share price gain since the earnings report signals investor confidence in Bruker's recent financial performance, which BRKR watchers will want to track.
The Touchstone Mid Cap Fund underperformed its benchmark, the Russell MidCap Index, for the quarter ended June 30, 2026. Bruker Corporation was listed among the largest contributors to the Fund's performance during this period.
Why it matters — A BRKR watcher would care because the fund review identifies Bruker as one of the top performers driving fund results during the quarter, signaling relative strength among mid-cap holdings.
Bruker announced an expanded strategic collaboration with Atinary Technologies, a developer of Self-Driving Labs and AI-driven R&D technologies, and made a minority investment in the company. Financial details were not disclosed. Atinary intends to integrate Chemspeed laboratory automation platforms, Bruker analytical instruments, and SciY software.
Why it matters — A Bruker watcher would care because the expanded partnership and minority stake signal deeper integration of Bruker instruments and software into AI-driven self-driving laboratory offerings, potentially broadening its reach in pharma, chemicals, energy, and materials.
Bruker Corporation announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and human tissue and disease models. The investment expands Bruker's post-genomic offerings for disease biology research and drug discovery into Microphysiological Systems (MPS) based on human physiology.
Why it matters — This move broadens Bruker's portfolio into human-physiology-relevant drug discovery and development tools, adding a new growth area in microphysiological systems for BRKR watchers.
Carillon Chartwell Mid Cap Value Fund published its Q2 2026 portfolio review. The review discusses holdings including ON Semiconductor, Knight-Swift Transportation, and Expand Energy, with no mention of Bruker Corp.
Why it matters — The item contains no information about Bruker Corp., so it offers no relevant insight for BRKR watchers.
The 13 Wall Street analysts covering Bruker Corp. have a median 12-month price target of $60, with estimates ranging from $40 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Bruker Corp., 8 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bruker Corp. 81 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Bruker Corp. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +1.0% from the last close, and Ticker Nerd's factor model ranks Bruker Corp. 81 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bruker Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $70 over the next 12 months.
Bruker Corp. returned +103.4% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Bruker Corp. is a scientific instruments and analytical solutions company that provides technologies for life science, materials research, and diagnostic applications.
The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Why Is Bruker (BRKR) Up 12.5% Since Last Earnings Report?". Bruker (BRKR) reported earnings 30 days ago and its stock has risen 12.5% since that report. The item discusses what may be next for the company following the earnings release.
Bruker Corp. is a scientific instruments and analytical solutions company that provides technologies for life science, materials research, and diagnostic applications. The company develops, manufactures, and distributes high-performance tools used to study matter at microscopic, molecular, and cellular levels, supporting research and testing across academic, clinical, industrial, and government settings. Its product portfolio includes magnetic resonance, mass spectrometry, X-ray, microscopy, metrology, chromatography, and molecular spectroscopy systems, along with specialized diagnostic and microbiology solutions. Bruker serves customers in biopharmaceuticals, in-vitro diagnostics, nanotechnology, semiconductor process control, and applied markets, making it an important supplier of advanced measurement and detection technologies in the global scientific equipment market.
CEO Dr. Frank H. Laukien Ph.D. · 11,085 employees · United States · https://www.bruker.com
